What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Antibiotics
His primary areas of study are Intensive care medicine, Pneumonia, Ventilator-associated pneumonia, Intensive care and Internal medicine.
The Intensive care medicine study combines topics in areas such as Antibiotics, Antibacterial agent, Emergency medicine, Drug resistance and Risk factor.
His Pneumonia research includes themes of Respiratory disease, Regimen and Cohort study.
Marin H. Kollef studied Ventilator-associated pneumonia and Epidemiology that intersect with Database.
His research in Intensive care intersects with topics in Clinical trial, Relative risk, Randomized controlled trial, Severity of illness and Intensive care unit.
Marin H. Kollef interconnects Methicillin-resistant Staphylococcus aureus, Vancomycin and Surgery in the investigation of issues within Internal medicine.
His most cited work include:
- Inadequate Antimicrobial Treatment of Infections: A Risk Factor for Hospital Mortality Among Critically Ill Patients (1588 citations)
- The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting (1518 citations)
- Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database (1028 citations)
What are the main themes of his work throughout his whole career to date?
Marin H. Kollef mainly investigates Intensive care medicine, Pneumonia, Internal medicine, Intensive care unit and Ventilator-associated pneumonia.
Marin H. Kollef studies Intensive care medicine, focusing on Intensive care in particular.
His Pneumonia research includes elements of Respiratory disease, Clinical trial and Epidemiology.
His Internal medicine study integrates concerns from other disciplines, such as Methicillin-resistant Staphylococcus aureus and Surgery.
Marin H. Kollef works mostly in the field of Intensive care unit, limiting it down to topics relating to Emergency medicine and, in certain cases, Emergency department, as a part of the same area of interest.
His Ventilator-associated pneumonia study frequently involves adjacent topics like Randomized controlled trial.
He most often published in these fields:
- Intensive care medicine (48.54%)
- Pneumonia (27.54%)
- Internal medicine (26.84%)
What were the highlights of his more recent work (between 2016-2021)?
- Intensive care medicine (48.54%)
- Internal medicine (26.84%)
- Pneumonia (27.54%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Intensive care medicine, Internal medicine, Pneumonia, Intensive care unit and Emergency medicine.
Interquartile range is closely connected to Antibiotics in his research, which is encompassed under the umbrella topic of Intensive care medicine.
His work focuses on many connections between Internal medicine and other disciplines, such as Meropenem, that overlap with his field of interest in Cefepime, Tazobactam and Adverse effect.
His Pneumonia research is multidisciplinary, incorporating perspectives in Clinical trial and Lung.
His Intensive care unit study incorporates themes from Drug resistance and Bacterial pneumonia.
His Emergency medicine research also works with subjects such as
- Emergency department which intersects with area such as Prospective cohort study, Mechanical ventilation and Cohort study,
- Sedation together with Delirium.
Between 2016 and 2021, his most popular works were:
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT) (289 citations)
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial (156 citations)
- A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial (88 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Antibiotics
Marin H. Kollef mainly focuses on Internal medicine, Pneumonia, Intensive care medicine, Ventilator-associated pneumonia and Retrospective cohort study.
His studies deal with areas such as Intensive care and Meropenem as well as Internal medicine.
His Pneumonia research incorporates themes from Clinical trial, Randomized controlled trial and APACHE II.
Many of his research projects under Intensive care medicine are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His biological study spans a wide range of topics, including Multiple drug resistance and Mechanical ventilation.
Marin H. Kollef interconnects De-escalation and Methicillin-resistant Staphylococcus aureus in the investigation of issues within Ventilator-associated pneumonia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
